Business
Evolus Provides Update on International Trade Commission (ITC) Case
Company Remains Confident in its Intellectual Property and the Overall Merits of the Case NEWPORT BEACH, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Evolus,
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"Company Remains Confident in its Intellectual Property and the Overall Merits of the Case\nNEWPORT BEACH, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) today provided the following statement:\n “In several media reports this week, Medytox has made comments on the International Trade Commission (ITC) case, which Evolus believes are speculative and intended to create confusion in the U.S. market ahead of the ITC Judge’s initial determination in June 2020 and the ITC’s final determination, which is targeted for October 2020. Importantly, nothing has changed as a result of the media reports from Korea. The ITC Judge will make his own independent decision based upon all the evidence presented at the hearing and through all of the parties’ filings. The Judge assigned to the ITC case is not obligated to accept a staff attorney’s position on the facts, and it’s fairly common for the Judge and the staff attorney to disagree on substantive matters. Evolus and Daewoong remain confident in the strength of our intellectual property and will continue to vigorously defend it through the entirety of the ITC process. In addition, numerous claims have been made in the Korean press regarding settlement discussions related to the ITC proceedings. It is the company’s policy to not confirm or comment on settlement discussions.” About the International Trade Commission (ITC) Proceedings Prior to the ITC hearings held February 4 - 7, and after the hearings, all parties involved in the case, including the staff attorney, were required to submit briefs to the Judge. This is a routine part of the proceedings. All of these briefs are currently posted as “confidential” on the ITC’s website. The “public” versions of the briefs are not yet available and are subject to redactions of confidential information prior to their release. About Evolus, Inc. Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points ex...